The efficacy of interferon-beta monotherapy for elderly patients with type C hepatitis of genotype 2

Internal Medicine

Volumn 48, Issue 16, 2009, Pages 1337-1342

  Arase, Yasuji ^a   Suzuki, Fumitaka ^a   Sezaki, Hitomi ^a   Kawamura, Yusuke ^a   Suzuki, Yoshiyuki ^a   Kobayashi, Masahiro ^a   Akuta, Norio ^a   Hosaka, Tetsuya ^a   Yatsuji, Hiromi ^a   Hirakawa, Miharu ^a   Kobayashi, Mariko ^a   Saitoh, Satoshi ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Elderly patients; Genotype 2a or 2b; Hepatitis C virus; Interferon monotherapy; Sustained virologicalresponse

Indexed keywords

BETA INTERFERON; VIRUS RNA;

AGE DISTRIBUTION; AGED; APPETITE DISORDER; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; FATIGUE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

AGE FACTORS; AGED; COHORT STUDIES; FEMALE; GENOTYPE; HEPATITIS C; HUMANS; INTERFERON-BETA; MALE; RETROSPECTIVE STUDIES;

EID: 70349548531     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.2252     Document Type: Article

References (28)

1. McHutchison JG, Poynard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology 119: 1317-1323, 2000.
2. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339: 1485-1492, 1998.
3. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 52: 1426-1432, 1998.
4. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha 2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 351: 83-87, 1998.
5. Lindsay KL, Trepo C, Heintges T, et al. Hepatitis Interventional Therapy Group. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34: 395-403, 2001.
6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment for chronic hepatitis C: a randomised trial. Lancet 358: 958-965, 2001.
7. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 25: 283-291, 1996.
8. Arase Y, Suzuki F, Suzuki Y, et al. Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C. Intern Med 46: 1827-1832, 2007.
9. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328: 1797-1801, 1993.
10. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 18: 47-53, 1993.
11. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112: 463-472, 1997.
12. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response interferon-alpha therapy in hepatitis C virus infection. Hepatology 19: 1088-1094, 1994.
13. Imai Y, Kasahara A, Tanaka H, et al. Interferon therapy for aged patients with chronic hepatitis C; improved survival in patients exhibiting a biochemical response. J Gastroenterol 39: 1069-1077, 2004.
14. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alpha therapy for chronic hepatitis C: A randomized, double blind placebo-controlled trial. N Engl J Med 321: 1506-1510, 1989.
15. Chayama K, Saitoh S, Arase Y, et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 13: 1040-1043, 1991.
16. Reichard O, Glaumann H, Fryden A, et al. Two-year biochemical, virological and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 21: 918-922, 1995.
17. Shiratori Y, Kato N, Yokosuka O, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 113: 558-566, 1997.
18. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334: 77-811, 1996.
19. Arase Y, Suzuki F, Sezaki H, et al. The efficacy of short-term interferon-beta therapy for type C cirrhotic patients with genotype 2a and low virus load. Intern Med 47: 1085-1090, 2008.
20. Doglio A, Laffont C, Caroli-Bosc FX, et al. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant. J Clin Microbiol 37: 1567-1569, 1999.
21. Albadalejo J, Alonso R, Antinozzi R, et al. Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory. J Clin Microbiol 36: 862-865, 1998.
22. Dusheiko G, Schmilovitz-Weiss H, Brown D, et al. Hepatitis C virus genotypes; an investigation of type-specific differences in geographic origin and disease. Hepatology 19: 13-18, 1994.
23. Ikeda K, Saitoh S, Kobayashi M, et al. Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data. Hepatol Res 18: 252-266, 2000.
24. Katamura Y, Suzuki F, Akuta N, et al. Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load. Intern Med 47: 1827-1834, 2008.
25. Dalgard O, Mangia A. Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection. Drugs 66: 1807-1815, 2006.
26. Tabaru A, Narita R, Hiura M, et al. Efficacy of short-term interferon therapy for patients infected with hepatitis C virus genotype 2a. Am J Gastroenterol 100: 862-867, 2005.
27. Sato Y, Tokuue H, Kawamura N, et al. Short-term interferon therapy for chronic hepatitis C patients with low viral load. Hepatogastroenterology 51: 968-972, 2004.
28. Fujiyama S, Chikazawa H, Honda Y, Tomita K. Effective interferon therapy for chronic hepatitis C patients with low viral loads. Hepatogastroenterology 50: 817-820, 2003.